GlassScriptPhysician profile
Angelito F Yango
NPI 1982651998
$3,991.47
in general payments reported to CMS, 2019-2025
34 companies · $1,329 in 2025
The $1,329 reported for 2025 was more than what 84% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $185 · 2021: $40.76 · 2022: $524 · 2023: $618 · 2024: $1,035 · 2025: $1,329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,959 · Education: $23.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,959.13 |
| Education | $23.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $590.98 | 2022-2025 | Krystexxa, Tavneos |
| Travere Therapeutics, INC. | $536.21 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $377.82 | 2019-2025 | Farxiga, Lokelma |
| Genzyme Corporation | $278.19 | 2019-2024 | |
| Vifor Pharma, INC. | $258.14 | 2020-2025 | Veltassa, Zemaira |
| Bayer Healthcare Pharmaceuticals INC. | $189.68 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $183.62 | 2020-2025 | Livtencity |
| Veloxis Pharmaceuticals, INC. | $178.92 | 2019-2025 | Envarsus |
| Mallinckrodt Hospital Products INC. | $166.53 | 2020-2025 | Terlivaz, Acthar |
| Horizon Therapeutics Plc | $161.34 | 2022-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.13 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $98.20 | 2024-2025 | |
| Mallinckrodt Enterprises LLC | $84.32 | 2019 | |
| Merck Sharp & Dohme LLC | $77.93 | 2023-2025 | Prevymis |
| Novo Nordisk INC | $68.54 | 2025 | Ozempic, Rivfloza, Rybelsus |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $66.59 | 2022-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $61.31 | 2019-2023 | Velphoro |
| Eurofins Viracor, LLC | $59.79 | 2022-2025 | |
| One Lambda, INC. | $49.80 | 2024 | |
| Ardelyx, INC. | $49.06 | 2024-2025 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $41.69 | 2022-2024 | Jynarque |
| Glaxosmithkline, LLC. | $33.84 | 2022-2025 | Shingrix, Arexvy |
| Melinta Therapeutics, LLC | $26.91 | 2025 | Rezzayo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $25.79 | 2025 | |
| Apellis Pharmaceuticals, INC. | $24.29 | 2025 | |
| Aurinia Pharma U.S., INC. | $24.06 | 2022 | |
| Dexcom, INC. | $22.55 | 2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $22.09 | 2025 | |
| Genentech USA, INC. | $21.74 | 2025 | Gazyva |
| Ani Pharmaceuticals, INC. | $21.70 | 2024 | Purified Cortrophin Gel |
| Ultragenyx Pharmaceutical INC. | $20.14 | 2020 | |
| Akebia Therapeutics INC | $15.38 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.00 | 2019 | |
| Opko Pharmaceuticals, LLC | $12.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angelito Yango listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.